vitro natural killer lymphokine-activated killer activity patients bronchogenic carcinoma authors peripheral blood mononuclear cells patients bronchogenic carcinoma natural killer NK lymphokine-activated killer LAK activity vitro incubation media media interferon gamma IFN U/ml U/ml results lymphocytes patients bronchogenic carcinoma LAK activity level activity lymphocytes control subjects cultures autologous human serum AHS specific release specific release LAK activity cytotoxicity NK-resistant cell line patients lymphocytes cells IFN Control unchanged significant difference groups patients different histologic types tumor different stages disease NK activity killing NK-sensitive target cells patients lymphocytes different controls lymphocytes specific release specific release studies feasibility IFN therapy patients bronchogenic carcinoma 